WithdrawnPhase 2

Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD

Stopped: Lack of funding

United States0Started 2024-10-01

Plain-language summary

The purpose of this study is to see if two treatments (extracorporeal photopheresis and Mesenchymal Stromal Cell (MSC) infusion, can be given safely together, and if they improve the symptoms of a Graft versus Host Disease (GvHD), a complication that can occur in people who undergo stem cell transplant.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓One of the following diagnoses:
✓-High risk aGVHD, either biopsy proven or clinical diagnosed as defined by either:
✓-Steroid refractory aGVHD (either biopsy proven or clinical diagnosed) as defined by any one of the following criteria per NCCN (National Comprehensive Cancer Network) Guidelines for Hematopoietic Cell Transplantation (HCT):

What they're measuring

Percent of participants with response to therapy

Timeframe: Day 28

Trial details

NCT IDNCT05333029

SponsorMolly Gallogly

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-01

View on ClinicalTrials.gov More Graft Versus Host Disease trials